Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?
Mary J Sabulski FeigmanMarcos M PiresPublished in: ACS infectious diseases (2018)
Drug resistance to our current stock of antibiotics is projected to increase to levels that threaten our ability to reduce and eliminate bacterial infections, which is now considered one of the primary health care crises of the 21st century. Traditional antibiotic agents (e.g., penicillin) paved the way for massive advances in human health, but we need novel strategies to maintain the upper hand in the battle against pathogenic bacteria. Nontraditional strategies, such as targeted immunotherapies, could prove fruitful in complementing our antibiotic arsenal.